Camelot Portfolios LLC Raises Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Camelot Portfolios LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,434 shares of the medical equipment provider’s stock after purchasing an additional 601 shares during the period. Camelot Portfolios LLC’s holdings in Zimmer Biomet were worth $468,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet in the third quarter worth about $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ZBH shares. Truist Financial restated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James dropped their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 1.2 %

ZBH stock opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The stock has a market cap of $20.88 billion, a P/E ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The business’s 50-day moving average price is $105.86 and its 200-day moving average price is $107.47. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 earnings per share. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.